

## **RNS<sup>®</sup> System Key Publications**

## **Clinical Outcomes**

Brain-responsive neurostimulation treatment in patients with GAD65 antibody-associated autoimmune mesial temporal lobe epilepsy Feyissa, et al. Epilepsia Open, 2020

Nine-year Prospective Safety and Effectiveness Outcomes from the Long-Term Treatment Trial of the RNS® System Nair, et al. Neurology, 2020

Real-world experience with direct brain-responsive neurostimulation for focal onset seizures Razavi, et al. Epilepsia, 2020

<u>Sleep disruption is not observed with brain-responsive neurostimulation</u> <u>for epilepsy</u>

Ruoff, L. et al. Epilepsia Open, 2020

<u>Treatment of drug-resistant epilepsy in patients with periventricular nodular</u> <u>heterotopia using RNS® System: efficacy and description of chronic</u> <u>electrophysiological recordings</u> <u>Nune, et al. Clinical Neurophysiology, 2019</u>

Responsive neurostimulation: Candidates and considerations Ma, B and Rao, V. Epilepsy and Behavior, 2018

<u>Sudden unexpected death in epilepsy in patients treated with brain-responsive</u> <u>neurostimulation</u>

Devinsky, et al. Epilepsia, 2017

Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy Geller et al. Epilepsia 2017

Brain-responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas Jobst, et al. Epilepsia, 2017



Infection and Erosion Rates in Trials of a Cranially Implanted Neurostimulator Do Not Increase with Subsequent Neurostimulator Placements Weber, et al. Stereotact Funct Neurosurg, 2017 Differential Neuropsychological Outcomes Following Responsive Targeted Neurostimulation for Partial Onset Epilepsy. Loring DW, et al. Epilepsia. 2015 Sep 19. Quality of life and mood in patients with medically intractable epilepsy. treated with targeted responsive neurostimulation Meador, K, et al. Epilepsy and Behavior, 2015 Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial Heck, et al, Epilepsia, 2014

## Data Insights

Mesial temporal resection following long-term ambulatory intracranial EEG monitoring with a direct brain-responsive neurostimulation system Hirsch, et al. Epilepsia, 2020

<u>Using Continuous Intracranial Electroencephalography Monitoring to</u> <u>Manage Epilepsy Patients During COVID-19</u> Mirro and Halpern. Neurosurgery, 2020

<u>Electrocorticographic events from long-term ambulatory brain recordings</u> <u>can potentially supplement seizure diaries</u> Quigg et al. Epilepsy Res 2020

Early detection rate changes from a brain-responsive neurostimulation system predict efficacy of newly added antiseizure drugs Quraishi et al. Epilepsia, 2020

<u>Quantitative electrocorticographic biomarkers of clinical outcomes in mesial</u> <u>temporal lobe epileptic patients treated with the RNS® system</u> Arcot Desai et al. Clinical Neurophysiol. 2019

<u>Multi-day rhythms modulate seizure risk in epilepsy</u> Baud, et al. Nature Communications, 2018



<u>Clinical and electrocorticographic response to antiepileptic drugs in</u> <u>patients treated with responsive stimulation</u> Skarpaas, et al. Epilepsy and Behavior, 2018

<u>Changes in the electrocorticogram after implantation of intracranial</u> <u>electrodes in humans: The implant effect.</u> Sun et al. Clinical Neurophysiol. 2018

<u>Circadian and ultradian patternsof epileptiform discharges differ by seizure-</u> <u>onset location during long-term ambulatory intracranial monitoring</u> <u>Spencer, et al. Epilepsia, 2017</u>

Rx Only. See important prescribing and safety information in the RNS<sup>®</sup> System labeling. This is intended as supplementary information and should be used in conjunction with the labeling. Refer to the labeling for a description of the RNS<sup>®</sup> System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use. The manuals are available at www.NeuroPace.com. ©2020 NeuroPace, Inc. All rights reserved. NeuroPace<sup>®</sup> and RNS<sup>®</sup> are registered trademarks of NeuroPace, Inc. NeuroPace, Inc. 455 N. Bernardo Ave., Mountain View, CA 94043. NP 150047 Rev 5/Rev. Date: 2020-08